Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerabilityResearch in context

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerabilityResearch in context

Summary: Background: Idiopathic pulmonary fibrosis (IPF) is an age-related, chronic, irreversible fibrotic lung disease. IPF is associated with increased senescent cells burden, which may be alleviated with administration of senescent cell targeting drugs termed ‘senolytics’. We previously conducte...

Full description

Bibliographic Details
Main Authors: Anoop Nambiar, Dean Kellogg, III, Jaime Justice, Martin Goros, Jonathan Gelfond, Rodolfo Pascual, Shahrukh Hashmi, Michal Masternak, Larissa Prata, Nathan LeBrasseur, Andrew Limper, Stephen Kritchevsky, Nicolas Musi, Tamara Tchkonia, James Kirkland
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:EBioMedicine
Subjects:
Senescence
Senolytics
Idiopathic pulmonary fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423000464

Similar Items

Similar Items